Janssen has entered into a collaboration with Achillion to develop and commercialize hepatitis C virus (HCV) medications. The ultimate goal is to develop a treatment that targets multiple genotypes of the virus and requires a short duration
The initial research will focus on Achillion’s NS5A inhibitor ACH-3102, which is currently being studied in Phase II trials and which the U.S. Food and Drug Administration (FDA) has granted Fast Track designation. The research will combine that drug with an NS3/4A protease inhibitor plus an NS5B polymerase inhibitor from the combined company portfolios included in the collaboration.
Janssen will have the exclusive, worldwide right to develop and, if approved, commercialize hep C therapies from the collaboration.